Bicycle Therapeutics plc (NASDAQ:BCYC) Insider Sells $69,646.87 in Stock

Bicycle Therapeutics plc (NASDAQ:BCYC) insider Santiago Arroyo sold 4,943 shares of the stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $14.09, for a total value of $69,646.87. Following the completion of the transaction, the insider now directly owns 69,057 shares of the company’s stock, valued at $973,013.13. This represents a 6.68 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Bicycle Therapeutics Stock Down 0.1 %

Shares of NASDAQ:BCYC opened at $14.88 on Tuesday. The company has a market cap of $1.03 billion, a PE ratio of -4.52 and a beta of 0.92. Bicycle Therapeutics plc has a fifty-two week low of $12.17 and a fifty-two week high of $28.67. The firm has a 50-day simple moving average of $19.27 and a 200 day simple moving average of $21.86.

Bicycle Therapeutics (NASDAQ:BCYC) last posted its earnings results on Thursday, October 31st. The company reported ($0.74) EPS for the quarter, beating the consensus estimate of ($0.78) by $0.04. The company had revenue of $2.68 million during the quarter, compared to analyst estimates of $6.82 million. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. The business’s revenue was down 50.0% compared to the same quarter last year. During the same period in the prior year, the company earned ($1.26) earnings per share. As a group, research analysts forecast that Bicycle Therapeutics plc will post -3.05 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the company. Needham & Company LLC reiterated a “buy” rating and set a $38.00 target price on shares of Bicycle Therapeutics in a research note on Thursday, October 31st. Cantor Fitzgerald reiterated an “overweight” rating on shares of Bicycle Therapeutics in a research note on Monday, September 9th. Royal Bank of Canada reissued an “outperform” rating and set a $35.00 price objective on shares of Bicycle Therapeutics in a report on Friday, November 1st. HC Wainwright cut their target price on shares of Bicycle Therapeutics from $55.00 to $33.00 and set a “buy” rating on the stock in a research note on Monday, December 16th. Finally, B. Riley decreased their price target on Bicycle Therapeutics from $28.00 to $17.00 and set a “neutral” rating for the company in a research note on Friday, December 13th. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $35.25.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the stock. Natixis Advisors LLC acquired a new position in shares of Bicycle Therapeutics during the second quarter valued at $261,000. TD Asset Management Inc lifted its position in Bicycle Therapeutics by 76.7% in the 2nd quarter. TD Asset Management Inc now owns 97,186 shares of the company’s stock valued at $1,967,000 after purchasing an additional 42,200 shares during the last quarter. Renaissance Technologies LLC boosted its stake in Bicycle Therapeutics by 97.2% during the 2nd quarter. Renaissance Technologies LLC now owns 326,800 shares of the company’s stock valued at $6,614,000 after purchasing an additional 161,100 shares during the period. L & S Advisors Inc grew its position in Bicycle Therapeutics by 16.1% in the 2nd quarter. L & S Advisors Inc now owns 58,335 shares of the company’s stock worth $1,181,000 after purchasing an additional 8,075 shares during the last quarter. Finally, XTX Topco Ltd acquired a new stake in shares of Bicycle Therapeutics in the second quarter valued at approximately $206,000. 86.15% of the stock is currently owned by institutional investors.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.